Get the Stockscreener App
471.32
1.17%
-5.57
After Hours:
471.32
Madrigal Pharmaceuticals Inc stock is traded at $471.32, with a volume of 287.53K.
It is down -1.17% in the last 24 hours and down -7.59% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$476.89
Open:
$477.93
24h Volume:
287.53K
Relative Volume:
0.92
Market Cap:
$10.87B
Revenue:
$1.13B
Net Income/Loss:
$-309.44M
P/E Ratio:
-36.82
EPS:
-12.8001
Net Cash Flow:
$-275.41M
1W Performance:
-3.45%
1M Performance:
-7.59%
6M Performance:
-14.69%
1Y Performance:
+66.95%
1-Day Range:
$471.32
$485.55
1-Week Range:
$465.00
$497.83
52-Week Range:
$275.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
471.32 | 11.00B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
435.71 | 113.14B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
601.65 | 64.60B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.18 | 54.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.22 | 39.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.19 | 31.79B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
MDGL: Rezdiffra’s blockbuster launch and expanding pipeline position the company for sustained growth - TradingView
Madrigal Investors Focus on Rezdiffra Growth at Goldman Event - MyChesCo
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound? - MSN
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Exploring A 39% Upside Potential - DirectorsTalk Interviews
Return on invested capital % of Madrigal Pharmaceuticals, Inc. – XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. News — XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. Statistics – XETR:YDO1 - TradingView
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com
(MDGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat - Investing.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress - Insider Monkey
Madrigal Highlights Rezdiffra Data as MASH Market Expands - MyChesCo
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 - The Manila Times
12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Madrigal Pharmaceuticals targets liver disease with Rezdiffra, eyeing strong growth despite competition risks. - Pluang
Madrigal Pharmaceuticals Could Become The Next Vertex - Seeking Alpha
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits - Quiver Quantitative
Insider Sell: David Soergel Sells Shares of Madrigal Pharmaceuti - GuruFocus
Madrigal Pharmaceuticals CMO David Soergel sells $516,561 in shares By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals CMO David Soergel sells $516,561 in shares - Investing.com
Madrigal (MDGL) CMO sells 1,042 shares in 10b5-1 trade, holds 10,033 - Stock Titan
MDGL (NASDAQ) insider files Form 144 reporting sale of 1,042 shares - Stock Titan
Citizens reiterates Madrigal Pharmaceuticals stock rating on liver data By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 35.71% Potential Upside - DirectorsTalk Interviews
Has Madrigal Pharmaceuticals (MDGL) Cracked the Code for MASH - Kavout
H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $620 - Moomoo
Madrigal Expands Workforce With Equity Hiring Grants - MyChesCo
Madrigal Pharmaceuticals (MDGL) Reports Positive Findings on Rez - GuruFocus
Madrigal Pharmaceuticals Says Data Show Rezdiffra Reduces Cardiovascular, Liver-Related Risks in MASH Patients - Moomoo
Madrigal Pharmaceuticals (MDGL) Reports Positive Findings on Rezdiffra for MASH Treatment - GuruFocus
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH - The Manila Times
Madrigal Presents Data Demonstrating Rezdiffra Reduced - GlobeNewswire
MASH drug Rezdiffra lowered key heart and liver risk signals - Stock Titan
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,928,716, According to a Recent SEC Filing - Moomoo
(MDGL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 30% Upside Beckons in the Biotech Sector - DirectorsTalk Interviews
MDGL Stock Price Prediction 2025-2026 | Madrigal Pharmaceuticals Inc Forecast - 24/7 Wall St.
Insider Sell: Richard Levy Sells Shares of Madrigal Pharmaceuticals Inc (MDGL) - GuruFocus
Director Richard Levy of Madrigal (MDGL) sells 5,682 shares under plan - Stock Titan
[144] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Madrigal Pharmaceuticals Inc (FRA:YDO1) Stock Price & 30 Year Financial Data - GuruFocus
Madrigal hires 15 staff, grants 5,308 stock units vesting over 4 years - Stock Titan
Madrigal to present Rezdiffra data at EASL Congress 2026 - Investing.com UK
Madrigal to present Rezdiffra data at EASL Congress 2026 By Investing.com - Investing.com South Africa
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk - GlobeNewswire
Liver disease drug Rezdiffra shows new data on heart risk markers - Stock Titan
Madrigal (NASDAQ: MDGL) CMO has 844 shares sold automatically for tax withholding - Stock Titan
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):